Global Fibrotic Diseases Treatment Market – Industry Trends and Forecast to 2031

Global Fibrotic Diseases Treatment Market, By Treatment (Medication, Organ Transplantation, Oxygen Therapy, Others), Application (Idiopathic Pulmonary Fibrosis, Hepatic Cirrhosis, Renal Fibrosis, Cutaneous Fibrosis, Others), End User (Hospitals, Specialty Clinics, Academic and Research Institutes, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) - Industry Trends and Forecast to 2031.

Fibrotic Diseases Treatment Market Analysis and Size

The fibrotic disease treatment market is driven by factors such as the rising prevalence of fibrotic diseases, an increase in the number of people smoking cigarettes, and technological advancement in the treatment of fibrosis diseases, leading to market growth. Currently, healthcare expenditure has increased across developed and emerging countries which is expected to create a competitive advantage for manufacturers to develop new and innovative products.

Data Bridge Market Research analyses that the global fibrotic diseases treatment market which was USD 3.62 billion in 2023, is likely to reach up to 6.19 billion by 2031, and is expected to undergo a CAGR of 5.5% during the forecast period. “Hospital" dominates the end user segment due to the rise in the awareness of proper treatment. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework

Report Scope and Market Segmentation

Market Definition

Fibrosis is a group of serious organ/tissue diseases that affect the tissue system. Fibrosis scars and thickens the tissue. It impacts the connecting tissue, for instance, in the lungs and the alveoli (air sacs inside the lungs). The lung damage gradually gets worse over time. Hard, stiff lung tissues don't expand as well as they should, making it harder to breathe. Pulmonary fibrosis may cause shortness of breath when you do routine tasks that never seemed tiring before.

 Global Fibrotic Diseases Treatment Market Dynamics

Drivers

• Rising Prevalence of Fibrotic Diseases

Due to various risk factors such as aging, obesity, high blood pressure (hypertension), or family history of fibrotic disease, patients with fibrotic diseases are rising globally and becoming a significant socio-economic issue. Thus, the rising number of patients with fibrotic diseases increases the demand for treatment, which acts as a driver in the market.

• Increase in the Number of People Smoking Cigarettes

Cigarette smoking is one of the most recognized risk factors for the development of Idiopathic Pulmonary Fibrosis (IPF). Furthermore, recent work suggests that smoking may have a detrimental effect on the survival of patients with IPF. Cigarette smoke contains particulate matter as well as numerous chemicals, including highly toxic RONS, which increases the swelling inside the body and hence lead to various diseases, including pulmonary fibrosis, and cancer among others, which is expected to drive the growth of the market.

• Technological Advancement in the Treatment of Fibrosis Diseases

IPF is characterized by the progressive accumulation of scar tissue in the lung and is associated with a median life expectancy of 2–4 years. Until recently, treatment options were limited, focusing on ineffective anti-inflammatory therapy, palliation, transplant, or trial recruitment. Increasing technological advancements for the detection and treatment of fibrotic diseases is expected to drive the growth of the market.

Opportunities

• Rising Research and Development Activities

The research and development activities have significantly opened various ways for the treatment of several diseases. The emerging technological advancements, along with the appropriate research, led to the formation of several drugs for the treatment of diseases. Most people associate a company's research and development function with the invention of new products. While inventions are important, the development of existing products is of equal significance as consumer preferences are continually changing. Rising research and development activities for fibrotic disease medications and treatment are expected to act as opportunities for the growth of the market.

• Development of New and More Effective Therapies

There are very few treatment options available for fibrotic diseases. These include medication which includes pirfenidone and nintedanib, oxygen therapy, organ transplantation, and pulmonary rehabilitation. Hence the rising development of new and more effective therapies for fibrotic diseases will provide new opportunities in the market.

Restraints/ Challenges

• High Cost of Medication and Treatments

Fibrotic disease treatments have become increasingly expensive due to the growing number of patients suffering from fibrosis and the risen prices of medical devices and medications. The modern technological devices used in fibrosis treatment are also playing a significant role in the high prices of treatments, and high accuracy. The high cost associated with the medication and treatment of fibrotic disease is expected to restrict the growth of the market.

• Lack of Effective Biomarkers and Diagnostic Tools

Biomarkers can be measurements of physiological and pathological processes or drug effects. The limited availability of chest imaging in developing countries is considered a chief obstacle to diagnosis since high-resolution computed tomography of the chest is the key diagnostic test for Idiopathic Pulmonary Fibrosis (IPF). Further, obtaining reliable lung function tests and providing treatment access is difficult in the more rural areas of these countries, which is expected to restrain the growth of the market.

• Complex and Multifactorial nature of Fibrotic Diseases

Although complex fibrotic disorders often cluster in families, they do not have a clear-cut pattern of inheritance. It may be difficult to identify the role of genetics in these disorders, particularly because families often also share environments and may have similar lifestyles. This makes it difficult to determine a person's risk of inheriting or passing on these disorders. Complex disorders are also difficult to study and treat because the specific factors that cause most of these disorders have not yet been identified. The complex and multifactorial nature of fibrotic disease is expected to challenge the market.

Recent Developments

• In May 2022, Boehringer Ingelheim, a leading research-driven biopharmaceutical company, and ArisGlobal, the global market leader in drug safety solutions worldwide, announced the acquisition of Boehringer Ingelheim's digital innovation, BRASS, by ArisGlobal. This data insights engine will be integrated into ArisGlobal's technology platform, LifeSphere, under the name of LifeSphere Clarity and will play a key role in driving industry-wide advancement of pharmacovigilance and patient safety. This has helped the company to expand its clinical diagnostics business across various regions in the world and helped to increase the global presence in the market
• In March 2022, Bristol Myers Squibb and Turning Point Therapeutics, Inc. announced a definitive merger agreement under which Bristol Myers Squibb acquired Turning Point Therapeutics for USD 76.00 per share. The transaction was unanimously approved by both the Bristol Myers Squibb and Turning Point Therapeutics Boards of Directors and was anticipated to close during the third quarter of 2022. This acquisition has helped the company to increase its global presence in the market

Global Fibrotic Diseases Treatment Market Scope

The fibrotic diseases treatment market is segmented on the basis of country, treatment, application, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Medication
• Organ Transplantation
• Oxygen Therapy
• Others

Application

• Idiopathic pulmonary fibrosis
• Hepatic cirrhosis
• Renal fibrosis
• Cutaneous fibrosis
• Others

End User

• Government organization
• Hospitals
• Academic and research institutes
• Others

Distribution Channel

• Hospital pharmacy
• Retail pharmacy
• Others

 Global Fibrotic Diseases Treatment Market Regional Analysis/Insights

The fibrotic diseases treatment market is analyzed and market size insights and trends are provided by treatment, application, end user, and distribution channel, as referenced above.

The countries covered in the fibrotic diseases treatment report are U.S., Canada, Mexico, Dominican Republic, Jamaica, Panama, Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Hungary, Lithuania, Austria, Ireland, Norway, Poland, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Taiwan, rest of Asia-Pacific, Brazil, Ecuador, Chile, Colombia, Venezuela, Argentina, Peru, Curaçao, Paraguay, Uruguay, Trinidad And Tobago, rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Kuwait, Israel, Bahrain, and rest of the Middle East and Africa.

North America is expected to dominate the market due to the increasing number of elderly individuals in the region. In addition, the market is driven by the high incidence of fibrotic diseases and the presence of major market players, all contributing to the growth of the market.

Asia-Pacific is expected to show the highest growth due to increasing technological advancement in developing areas.

The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as downstream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.

 Healthcare Infrastructure growth Installed base and New Technology Penetration

The fibrotic diseases treatment market also provides you with detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the global Fibrotic Diseases Treatment market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the fibrotic diseases treatment market. The fibrotic diseases treatment market The data is available for historic period 2010-2020.

Competitive Landscape and Global Fibrotic Diseases Treatment Market Share Analysis

The fibrotic diseases treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the fibrotic diseases treatment market.

Some of the major players operating in the fibrotic diseases treatment market are:

• Genentech, Inc. - (U.S.)
• C.H. Boehringer Ingelheim International GmbH - (Germany)
• AbbVie Inc. - (U.S.)
• Redx Pharma Plc - (U.K.)
• Bristol-Myers Squibb Company - (U.S.)
• BellBrook Labs - (U.S.)
• Enveda Biosciences - (U.S.)
• BioMX - (U.S.)
• Gilead Sciences, Inc. - (U.S.)
• KITHER BIOTECH S.R.L. - (Italy)
• Verona Pharma plc - (U.K.)
• Alpine Immune Sciences - (U.S.)
• Intercept Pharmaceuticals, Inc. - (U.S.)
• Pharmaxis Ltd - (Australia)
• Teva Pharmaceutical Industries Ltd. - (Israel)
• Sandoz International GmbH - (Germany)
• Accord Healthcare - (U.K.)
• Camber Pharmaceuticals, Inc. - (United States